Lung Cancer and Stem Cells

Lung cancer is the leading cause of cancer-related deaths worldwide, with 1.8 million people dying from the disease in 2015. Despite advances in treatment, the 5-year survival rate for lung cancer remains low at just 18%. This is largely due to the fact that the disease is often diagnosed at an advanced stage, when it is difficult to treat. Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in a variety of tissues, including the bone marrow, adipose tissue, and lung. MSCs have the ability to self-renew and differentiate into a variety of cell types, including lung cells. The use of MSCs in the treatment of lung cancer is a promising new approach that is currently being investigated in clinical trials. MSCs have several potential advantages over traditional treatment modalities, including their ability to home to areas of tumor growth and their immunomodulatory properties. In a phase I clinical trial, MSCs were injected into the lungs of patients with advanced lung cancer. The MSCs were well-tolerated and no serious side effects were observed. Preliminary data from this trial suggest that MSCs may have anti-tumor activity in lung cancer. MSCs are a promising new treatment option for lung cancer. Further clinical trials are needed to determine the efficacy and safety of MSCs in the treatment of this disease.

 "Lung cancer stem cells—origin, characteristics and therapy - PMC." 14 Mar. 2018, Accessed 20 Oct. 2022.

 "Lung Cancer Stem Cell Markers as Therapeutic Targets - Frontiers." Accessed 20 Oct. 2022.

 "Lung cancer stem cells—characteristics, phenotype - Hardavella." Accessed 20 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
Myers cocktail/NAD1N/A